The content on this site is intended for healthcare professionals only
The panel discuss the key points that emerged from the first day of the 10th iwNHL meeting in Boston. Topics include the role of antigenic drive of B-cells in different lymphomas, the prospect of curative therapies for front line diffuse large B-cell lymphoma, potential new therapies to target B-cell receptor signalling pathways and treatment options for T-cell lymphoma.
In addition, the panel discuss a number of concerns that have emerged. These include the need for additional research clarifying the value of maintenance therapies, uncertainty of the biology and mechanism of action of new CNS treatments and concerns over the choice of patients for clinical trials
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
More effective treatment options required for patients with MM post lenalidomide exposure
